Nitazoxanide and COVID-19: A review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11033-022-07822-2.pdf
Reference61 articles.
1. Al-Kuraishy HM et al (2021) Case report: hyperbilirubinemia in Gilbert Syndrome attenuates Covid-19-induced metabolic disturbances. Front Cardiovasc Med 8:642181
2. Tilmanis D et al (2020) Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir. Antiviral Res 180:104851
3. Rossignol JF, Bréchot C (2019) A pilot clinical trial of nitazoxanide in the treatment of chronic hepatitis B. Hepatol Commun 3(6):744–747
4. Fox LM, Saravolatz LD (2005) Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 40(8):1173–1180
5. Dubreuil L et al (1996) In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 40(10):2266–2270
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Nitazoxanide reduces inflammation and bone erosion in mice with collagen-induced arthritis via inhibiting the JAK2/STAT3 and NF-κB pathways in fibroblast-like synoviocytes;Biomedicine & Pharmacotherapy;2024-02
2. Amebicides against Acanthamoeba castellanii: The Impact of Organism Models Used in Amebicide Assays;Parasitologia;2024-01-01
3. Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review;Clinical Case Reports;2023-11
4. SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway;Cell Stress and Chaperones;2023-11
5. Irisin/PGC-1α/FNDC5 pathway in Parkinson’s disease: truth under the throes;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-10-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3